The stock of Arcadia Biosciences Inc (NASDAQ: RKDA) has increased by 0.43% when compared to last closing price of $4.63.Despite this, the company has seen a gain of 6.16% in its stock price over the last five trading days. seekingalpha.com reported 2025-05-11 that Arcadia Biosciences, Inc. (NASDAQ:RKDA ) Q1 2025 Earnings Conference Call May 8, 2025 2:00 PM ET Company Participants Mark Kawakami – Chief Financial Officer T.J. Schaefer – President and Chief Executive Officer Conference Call Participants Ben Klee – Lake Street Operator Hello, and welcome to Arcadia Biosciences First Quarter 2025 Financial Results and Business Highlights Conference Call.
Is It Worth Investing in Arcadia Biosciences Inc (NASDAQ: RKDA) Right Now?
RKDA has 36-month beta value of 0.50. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy”, 0 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for RKDA is 1.36M, and currently, short sellers hold a 1.64% ratio of that float. The average trading volume of RKDA on July 04, 2025 was 15.19K shares.
RKDA’s Market Performance
RKDA stock saw an increase of 6.16% in the past week, with a monthly gain of 0.87% and a quarterly increase of 73.97%. The volatility ratio for the week is 9.77%, and the volatility levels for the last 30 days are 7.43% for Arcadia Biosciences Inc (RKDA). The simple moving average for the last 20 days is -0.43% for RKDA’s stock, with a simple moving average of 14.39% for the last 200 days.
Analysts’ Opinion of RKDA
Many brokerage firms have already submitted their reports for RKDA stocks, with H.C. Wainwright repeating the rating for RKDA by listing it as a “Buy”. The predicted price for RKDA in the upcoming period, according to H.C. Wainwright is $12 based on the research report published on August 17, 2020 of the previous year 2020.
Credit Suisse gave a rating of “Outperform” to RKDA, setting the target price at $14 in the report published on June 09th of the previous year.
RKDA Trading at 8.24% from the 50-Day Moving Average
After a stumble in the market that brought RKDA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.90% of loss for the given period.
Volatility was left at 7.43%, however, over the last 30 days, the volatility rate increased by 9.77%, as shares surge +0.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +53.47% upper at present.
During the last 5 trading sessions, RKDA rose by +6.16%, which changed the moving average for the period of 200-days by +66.67% in comparison to the 20-day moving average, which settled at $4.67. In addition, Arcadia Biosciences Inc saw 47.62% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RKDA starting from Kawakami Mark, who purchase 700 shares at the price of $2.49 back on Feb 03 ’25. After this action, Kawakami Mark now owns 2,681 shares of Arcadia Biosciences Inc, valued at $1,743 using the latest closing price.
Schaefer Thomas J., the Chief Executive Officer of Arcadia Biosciences Inc, purchase 700 shares at $2.49 during a trade that took place back on Feb 03 ’25, which means that Schaefer Thomas J. is holding 2,819 shares at $1,743 based on the most recent closing price.
Stock Fundamentals for RKDA
Current profitability levels for the company are sitting at:
- -0.29% for the present operating margin
- 0.4% for the gross margin
The net margin for Arcadia Biosciences Inc stands at -0.38%. The total capital return value is set at -0.14%. Equity return is now at value -7.89%, with -5.30% for asset returns.
Based on Arcadia Biosciences Inc (RKDA), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -381.19.
Currently, EBITDA for the company is -7.5 million with net debt to EBITDA at 0.57. When we switch over and look at the enterprise to sales, we see a ratio of 0.61. The receivables turnover for the company is 0.7for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.99.
Conclusion
To put it simply, Arcadia Biosciences Inc (RKDA) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
